Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting
SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that new data from the Sightline study of Lung EpiCheck® will be presented by Dr. Peter Mazzone from Cleveland Clinic in a late-breaking rapid-fire original investigations session during the American College of Chest Physicians (CHEST) 2023 Annual Meeting, October 8-11 in Honolulu.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.